Sort   by:  
 Page size 
UnknownChloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
Chloroquine and hydroxychloroquine belong to the aminoquinoline drugs. Studies revealed that chloroquine and hydroxychloroquine shows antagonism activity against COVID-19 under laboratory conditions. ARDS and ALI are conditions that occur in patients with COVID-19 as the main pathological complicati...
S-EPMC7792551 | biostudies-literature
UnknownCOVID-19-induced immune thrombocytopenic purpura; Immunopathogenesis and clinical implications.
Following the outbreak of the COVID-19 pandemic, millions of people around the world have been affected with SARS-CoV-2 infection. In addition to the typical symptoms, thrombotic events, lymphopenia, and thrombocytopenia have been reported in COVID-19 patients. Immune thrombocytopenic purpura (ITP) ...
S-EPMC8929732 | biostudies-literature
UnknownTranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.
SARS-CoV-2 is a type of beta-CoV that develops acute pneumonia, which is an inflammatory condition. A cytokine storm has been recognized as one of the leading causes of death in patients with COVID-19. ALI and ARDS along with multiple organ failure have also been presented as the consequences of acu...
S-EPMC8146296 | biostudies-literature
Sort   by:  
 Page size